PHK
CHRS icon

Point72 Hong Kong’s Coherus Oncology CHRS Stock Holding History

Point72 Hong Kong’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,108
Closed -$174K – 342
2022
Q3 		$174K Buy
18,108
+16,355
+933% +$166K 0.01% 1086
2022
Q2 		$13K Sell
1,753
-11,344
-87% -$98.6K ﹤0.01% 1640
2022
Q1 		$169K Buy
13,097
+5,639
+76% +$71.7K 0.01% 1016
2021
Q4 		$119K Buy
+7,458
New +$130K ﹤0.01% 1140
2021
Q3 		– Sell
-17,617
Closed -$244K – 2023
2021
Q2 		$244K Buy
+17,617
New +$249K 0.01% 1104
2019
Q4 		– Sell
-199
Closed -$4K – 1185
2019
Q3 		$4K Sell
199
-432
-68% -$8.63K ﹤0.01% 825
2019
Q2 		$14K Buy
+631
New +$11K ﹤0.01% 824
2019
Q1 		– Sell
-14
Closed – – 1048
2018
Q4 		$0 Sell
14
-108
-89% -$1.25K ﹤0.01% 928
2018
Q3 		$2K Buy
+122
New +$2.16K ﹤0.01% 767
2018
Q1 		– Sell
-1,638
Closed -$14K – 932
2017
Q4 		$14K Buy
+1,638
New +$17.5K 0.01% 434
2017
Q3 		– Sell
-3,328
Closed -$48K – 830
2017
Q2 		$48K Buy
+3,328
New +$64K 0.05% 228
2017
Q1 		– Sell
-485
Closed -$14K – 755
2016
Q4 		$14K Sell
485
-2,315
-83% -$64.8K 0.01% 599
2016
Q3 		$75K Buy
+2,800
New +$76.4K 0.04% 395

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Hong Kong's CHRS Position: Q4 2022 in Review

Point72 Hong Kong sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 18,108 shares — an estimated $174K sold.

Point72 Hong Kong first reported a position in CHRS in Q3 2016 and held it in 13 quarters. The position peaked at $244K in Q2 2021. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Point72 Hong Kong reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 18,108 Coherus Oncology shares in Q4 2022, an estimated $174K.
  • Point72 Hong Kong first reported a position in Coherus Oncology in Q3 2016 and held it in 13 quarters.
  • Point72 Hong Kong's Coherus Oncology position peaked at $244K in Q2 2021.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.